由于ENPP1缺陷 (ARHR2) 导致的2型自体逆性低酸性精神疾病
Thomas Edouard1, Agnès Linglart2
1Endocrine, Bone Diseases and Genetics Unit, Reference Centre for Rare Diseases of Calcium and Phosphate Metabolism, OSCAR Network, ERN BOND, Children's Hospital, Toulouse University Hospital; RESTORE, INSERM U1301, Paul Sabatier University; Toulouse, France.
2型自体递归性低酸性恶心病 (ARHR2) 是一种罕见的ENPP1基因疾病,导致恶心病和骨质疏松症. 基因确认对于适当的治疗和临床试验资格至关重要.
科学领域:
- 遗传学 遗传学 是一个
- 生物化学 生物化学
- 儿科 儿科 儿科
背景情况:
- 2型自体递归性低酸性恶心病 (ARHR2) 是一种罕见的遗传性疾病.
- 它是由ENPP1基因中的双基功能丧失突变引起的.
- 恩普1缺陷呈现了一系列表型,包括GACI,OPLL和PXE,ARHR2有时是最初的表现.
研究的目的:
- 总结ARHR2.2的临床和遗传方面的情况.
- 要突出ENPP1缺乏,FGF23升高和低酸血之间的联系.
- 强调基因确认对患者管理和临床试验参与的重要性.
主要方法:
- 审查关于ENPP1缺陷和ARHR2.2的现有文献.
- 分析受影响患者的临床和遗传数据.
- 将ARHR2表型与其他低血性狂犬病的比较.
主要成果:
- ARHR2是由ENPP1突变引起的,通过升高的FGF23.2导致低酸血症.
- 患者表现出恶心和骨质疏松症,并可能同时出现与GACI相关的特征,如子宫外和聋.
- 现型严重程度各不相同,ARHR2可以独立表现或在GACI幸存者中表现出来.
结论:
- 对ENPP1突变的遗传确认对于诊断ARHR2至关重要.
- 了解ENPP1缺陷频谱有助于患者管理.
- 准确的诊断有助于获得针对性疗法和新型酶替代疗法的临床试验.
更多相关视频
09:34Targeted Next-generation Sequencing and Bioinformatics Pipeline to Evaluate Genetic Determinants of Constitutional Disease
Published on: April 4, 2018
07:13Two Techniques to Create Hypoparathyroid Mice: Parathyroidectomy Using GFP Glands and Diphtheria-Toxin-Mediated Parathyroid Ablation
Published on: March 14, 2017
相关概念视频
Inborn Errors of Metabolism
Overview of Protein Metabolism
Amino acids play various roles in the body once they are absorbed into cells. They are restructured...
The Retinoblastoma Gene
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
Bone Disorders
Bone deposition is also affected by the levels of sex hormones like estrogen and testosterone that promote osteoblast activity and bone matrix synthesis. When the level of these hormones decreases due to aging, it causes a reduction in bone deposition. As a result, bone resorption by osteoclasts...
Pedigree Analysis
Chronic Kidney Disease II: Clinical Manifestations
